April 20, 2025
Financial Assets

Is buying art a good financial investment? Here’s everything we know

Artists push Native art to evolve using new techniques and materials Artists discuss how Native art evolved and why many don’t have the same regard and access to mainstream galleries and museums as non-Indigenous peers. While art can appreciate in value, it’s difficult to determine trends and pricing information is limited. Experts suggest focusing on

Read More
Intangible Assets

Green Bay area grocery stores prepare for 2025 NFL draft

Seven things to know about the 2025 NFL draft in Green Bay Here are a few things to know about the 2025 NFL draft being held April 24-26 in Green Bay. Green Bay grocery stores are increasing inventory and adjusting delivery schedules in anticipation of the 2025 NFL draft. Metro Market, located near the draft

Read More
Intangible Assets

Greater Boston real estate pros expect strong spring housing market

Tour of 171 Marsh St., Belmont, former home of Gov. Mitt Romney Tour of 171 Marsh St., Belmont, former home of 2012 presidential candidate and Massachusetts’s 70th governor, Mitt Romney. Joanna K. Tzouvelis, wickedlocal.com The median price for a single-family home in Massachusetts rose to $575,000 in February, a 4.9% increase from the previous year.

Read More
Operating Assets

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

–  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases –  Lead target and indication to be announced MY 2025 –  Cash balance of $185.2 million expected to fund operations into 2H 2027 Get the latest news delivered to your inbox Sign up for The Manila Times

Read More
Operating Assets

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations –

Read More
Operating Assets

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the 3rd line and later setting at the

Read More
Operating Assets

BCSO regional law enforcement training center proposed for site in Viera

The Brevard County Sheriff’s Office is planning to build a $20 million complex near the Brevard County Government Center in Viera that will include a regional training center for law enforcement personnel. BSCO has submitted a $10 million funding request to the Florida Legislature to help pay for the facility. The request for state funding

Read More
Operating Assets

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase

Read More
Operating Assets

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million

Read More
Operating Assets

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with

Read More